Aligos Therapeutics Begins Dosing with NASH Drug Candidate, ALG-055009, in Healthy Volunteers in a Phase 1 First-in-Human Study
December 09, 2021 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Presents Update of Chronic Hepatitis B Pipeline Portfolio at HEP DART 2021
December 07, 2021 08:00 ET
|
Aligos Therapeutics
New data from HBeAg-positive patients receiving 100 mg of ALG-000184 demonstrates similar PK and potent antiviral activity to previously reported data for HBeAg-negative patients New preclinical data...
Aligos Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Appoints Bridget Martell, MA, M.D., to its Board of Directors
November 18, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Present Virtually at the Jefferies London Healthcare Conference 2021
November 15, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021
November 12, 2021 08:00 ET
|
Aligos Therapeutics
Several clinical and nonclinical posters to be presented at the conference Aligos’ capsid assembly modulator (CAM) candidate, ALG-000184, achieved rapid, substantial reductions in hepatitis B virus...
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Aligos Therapeutics
Dosing of ALG-020572 (ASO) in healthy volunteers underway Enrollment in first 2 STOPS cohorts (120, 200 mg) complete; enrollment in 3rd cohort (400 mg) underway Clinical trial application (CTA)...
Aligos Therapeutics to Announce Third Quarter 2021 Results November 4, 2021
October 28, 2021 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Present Data for its Clinical Portfolio Targeting Chronic Hepatitis B and NASH at AASLD’S The Liver Meeting® 2021
October 14, 2021 16:58 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Begins Dosing with Antisense Oligonucleotide Drug Candidate, ALG-020572, in Healthy Volunteers in a Phase 1 Proof-of-Concept Study
October 11, 2021 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...